Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Polyzois Makras

Showing results (11-20 of 139) with videos related to

Pageof 14
Sort By:
Metabolism: Clinical and Experimental|August 17, 2015
Novel therapies for osteoporosisPolyzois Makras, Sideris Delaroudis, Athanasios D Anastasilakis
Journal of Clinical Medicine|February 25, 2022
Adult Langerhans Cell Histiocytosis and the SkeletonDanae Georgakopoulou, Athanasios D Anastasilakis, Polyzois Makras
The Journal of Clinical Endocrinology and Metabolism|September 8, 2016
Letter to the Editor: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic AcidPolyzois Makras, Stergios A Polyzos, Athanasios D Anastasilakis
Maturitas|May 13, 2017
Bisphosphonates or denosumab discontinuation and risk of fracturesAthanasios D Anastasilakis, Maria P Yavropoulou, Polyzois Makras
Expert Opinion on Investigational Drugs|August 25, 2017
Investigational anabolic agents for the treatment of osteoporosis: an update on recent developmentsAnastasia D Dede, Polyzois Makras, Athanasios D Anastasilakis
Expert Opinion on Pharmacotherapy|May 16, 2019
Bazedoxifene for the treatment of osteoporosisMaria P Yavropoulou, Polyzois Makras, Athanasios D Anastasilakis
European Journal of Endocrinology|April 26, 2018
THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosisAthanasios D Anastasilakis, Stergios A Polyzos, Polyzois Makras
Endocrine|May 23, 2020
Magnetic resonance imaging has an advantage over conventional spine X-rays in the evaluation of rebound-associated vertebral fractures following denosumab discontinuationAthanasios D Anastasilakis, Gerasimos Evangelatos, Polyzois Makras, et al.
Bone Reports|May 7, 2020
Rebound-associated vertebral fractures may occur in sequential time points following denosumab discontinuation: need for prompt treatment re-initiationAthanasios D Anastasilakis, Gerasimos Evangelatos, Polyzois Makras, et al.
Journal of Musculoskeletal & Neuronal Interactions|September 3, 2019
Lessons learned from the management of Hungry Bone Syndrome following the removal of an Atypical Parathyroid AdenomaDimos Florakis, Stavros Karakozis, Sophia Tseleni-Balafouta, et al.
Pageof 14

Showing results (11-20 of 139) with videos related to

Sort By:
Pageof 14
Metabolism: Clinical and Experimental|August 17, 2015
Novel therapies for osteoporosisPolyzois Makras, Sideris Delaroudis, Athanasios D Anastasilakis
Journal of Clinical Medicine|February 25, 2022
Adult Langerhans Cell Histiocytosis and the SkeletonDanae Georgakopoulou, Athanasios D Anastasilakis, Polyzois Makras
The Journal of Clinical Endocrinology and Metabolism|September 8, 2016
Letter to the Editor: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic AcidPolyzois Makras, Stergios A Polyzos, Athanasios D Anastasilakis
Maturitas|May 13, 2017
Bisphosphonates or denosumab discontinuation and risk of fracturesAthanasios D Anastasilakis, Maria P Yavropoulou, Polyzois Makras
Expert Opinion on Investigational Drugs|August 25, 2017
Investigational anabolic agents for the treatment of osteoporosis: an update on recent developmentsAnastasia D Dede, Polyzois Makras, Athanasios D Anastasilakis
Expert Opinion on Pharmacotherapy|May 16, 2019
Bazedoxifene for the treatment of osteoporosisMaria P Yavropoulou, Polyzois Makras, Athanasios D Anastasilakis
European Journal of Endocrinology|April 26, 2018
THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosisAthanasios D Anastasilakis, Stergios A Polyzos, Polyzois Makras
Endocrine|May 23, 2020
Magnetic resonance imaging has an advantage over conventional spine X-rays in the evaluation of rebound-associated vertebral fractures following denosumab discontinuationAthanasios D Anastasilakis, Gerasimos Evangelatos, Polyzois Makras, et al.
Bone Reports|May 7, 2020
Rebound-associated vertebral fractures may occur in sequential time points following denosumab discontinuation: need for prompt treatment re-initiationAthanasios D Anastasilakis, Gerasimos Evangelatos, Polyzois Makras, et al.
Journal of Musculoskeletal & Neuronal Interactions|September 3, 2019
Lessons learned from the management of Hungry Bone Syndrome following the removal of an Atypical Parathyroid AdenomaDimos Florakis, Stavros Karakozis, Sophia Tseleni-Balafouta, et al.
Pageof 14